BioSpace News Archive

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced that Chief Executive Officer John P. Furey will be presenting at the following upcoming investor conferences.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of four new patents, two in the U.S. and two in China.

Neogene Therapeutics, Inc. today announced the approval of the company’s first Clinical Trial Application (CTA) by the Dutch regulatory authority for a Phase 1 study of NT-125, an autologous, fully-individualized, multi-specific TCR therapy for the treatment of advanced solid tumors.

May 10, 2022-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, today announced that it will be participating in the 2022 UBS Global Healthcare Conference taking place at the Lotte New York Palace, New York, NY, on May 23-25, 2022.

Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research.

Biobohemia’s scientists share in a released paper (Changing Landscape of Cancer Vaccines-Novel Proteomics Platform for New Antigen Compositions).

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today provided company updates and reported consolidated first quarter 2022 financial results.

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical trial combining ZEN-3694 + Pfizer Inc.’s Talzenna (talazoparib).

PsiloTec Health Solutions Inc., is pleased to announce it has received approval from the Health Research Ethics Board of Alberta (the “HREBA”) to conduct a phase II clinical study for patients suffering from treatment-resistant depression (“TRD”).

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”), a clinical-stage, biopharmaceutical company today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022.